Anti-inflammatory effects of propofol during cardiopulmonary bypass: a pilot study

Document Type


Publication Date


Publication Title

Ann Card Anaesth


INTRODUCTION: Propofol has been suggested as a useful adjunct to cardiopulmonary bypass (CPB) because of its potential protective effect on the heart mediated by a decrease in ischemia-reperfusion injury and inflammation at clinically relevant concentrations. In view of these potentially protective properties, which modulate many of the deleterious mechanism of inflammation attributable to reperfusion injury and CPB, we sought to determine whether starting a low dose of propofol infusion at the beginning of CPB would decrease inflammation as measured by pro-inflammatory markers.

MATERIALS AND METHODS: We enrolled 24 patients undergoing elective coronary artery bypass graft (CABG). The study group received propofol at rate of 120 mcg/kg/min immediately after starting CPB and was maintained throughout the surgery and for the following 6 hours in the intensive care unit (ICU). The control group received propofol dose of 30-50 mcg/kg/min which was started at the time of chest closure with wires and continued for the next 6 hours in the ICU. Interleukins (IL) -6, -8 and -10 and tumor necrosis factor alpha (TNFalpha) were assayed.

RESULT: The most significant difference was in the level of IL-6 which had a P value of less than 0.06. Starting a low dose propofol early during the CPB was not associated with significant hemodynamic instability in comparison with the control group.

CONCLUSION: Our study shows that propofol may be suitable as an anti-inflammatory adjunct for patients undergoing CABG.

Medical Subject Headings

Analysis of Variance; Anesthetics, Intravenous; Anti-Inflammatory Agents; Cardiopulmonary Bypass; Female; Humans; Inflammation; Male; Pilot Projects; Propofol; Prospective Studies

PubMed ID






First Page


Last Page